Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study

BACKGROUND: The majority of patients with advanced gastrointestinal stromal tumours (GISTs) develop resistance to imatinib and sunitinib, the standard of care for these patients. This study evaluated the combination of buparlisib, an oral phosphoinositide 3-kinase (PI3K) inhibitor, with imatinib in...

Descripción completa

Detalles Bibliográficos
Autores principales: Gelderblom, Hans, Jones, Robin L., George, Suzanne, Valverde Morales, Claudia, Benson, Charlotte, Jean-Yves Blay, Renouf, Daniel J., Doi, Toshihiko, Le Cesne, Axel, Leahy, Michael, Hertle, Sabine, Aimone, Paola, Brandt, Ulrike, Schӧffski, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156686/
https://www.ncbi.nlm.nih.gov/pubmed/32147671
http://dx.doi.org/10.1038/s41416-020-0769-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156686/
https://www.ncbi.nlm.nih.gov/pubmed/32147671
http://dx.doi.org/10.1038/s41416-020-0769-y

Ejemplares similares